Abstract: Objective:To investigate the effectiveness of an enhanced recovery after surgery (ERAS)–based multidisciplinary management model in patients with diabetic neurogenic bladder (DNB). Methods:This prospective randomized controlled trial enrolled 90 patients with DNB admitted between January 2023 and June 2024. Patients were randomly assigned to an experimental group or a control group, with 45 cases in each group. The control group received conventional management, while the experimental group underwent ERAS-based multidisciplinary management. Length of hospital stay and hospitalization costs were compared between the two groups. Glycemic parameters, urodynamic indices (postvoid residual urine volume, maximum urinary flow rate, maximum detrusor pressure, and maximum cystometric capacity), scale scores (AUA-SI, PHQ-9, and SF-Qualiveen), and DNB-related complications (urinary tract infection, urinary calculi, and upper urinary tract dilatation) were evaluated at baseline and at 3 and 6 months after intervention. Repeated-measures analysis of variance and generalized estimating equations were used to assess the effects of management.Results: The experimental group had significantly shorter length of hospital stay and lower hospitalization costs than the control group (P<0.05). Repeated-measures analysis of variance showed significant time effects, group effects, and time-by-group interaction effects for 2-hour postprandial glucose, four urodynamic parameters, and scale scores (AUA-SI and SF-Qualiveen) (all P<0.05). Glycated hemoglobin and PHQ-9 scores showed significant time effects and interaction effects (P<0.05). No significant time-by-group interaction effect was observed for fasting plasma glucose (P> 0.05), whereas its time effect was statistically significant (P < 0.05). Generalized estimating equation analysis revealed significant time and group effects for urinary tract infection (P<0.05), while urinary calculi and upper urinary tract dilatation showed significant time effects only (P<0.05).Conclusion: ERAS-based multidisciplinary collaborative management improves glycemic control, bladder function, and quality of life in patients with DNB, reduces hospital stay and medical costs, and may contribute to a reduction in certain complications, indicating potential value for clinical application.